Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing

Phillip James, David Stoddart, Eoghan D Harrington, John Beaulaurier, Lynn Ly, Stuart W Reid, Daniel J Turner, View ORCID ProfileSissel Juul
doi: https://doi.org/10.1101/2020.08.07.20161737
Phillip James
1Oxford Nanopore Technologies Ltd., Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Stoddart
1Oxford Nanopore Technologies Ltd., Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eoghan D Harrington
2Oxford Nanopore Technologies Inc., New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Beaulaurier
3Oxford Nanopore Technologies Inc., San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lynn Ly
3Oxford Nanopore Technologies Inc., San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stuart W Reid
1Oxford Nanopore Technologies Ltd., Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel J Turner
1Oxford Nanopore Technologies Ltd., Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sissel Juul
2Oxford Nanopore Technologies Inc., New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sissel Juul
  • For correspondence: sissel.juul@nanoporetech.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

LamPORE™ is a rapid way of testing/screening large numbers of samples for the presence or absence of SARS-CoV-2, the virus causing COVID-19. It combines barcoded multi-target amplification, 15-minute barcoded library preparation and real-time nanopore sequencing. Starting with extracted RNA, results can be obtained from 12 samples in approximately an hour and from 96 samples in under 2 hours. High scalability is achieved by combinatorial barcoding. Performance characteristics are currently being established and regulatory clearance to market is underway.

Competing Interest Statement

All authors are employees of Oxford Nanopore Technologies and are shareholders and/or share option holders.

Funding Statement

All authors are employees of Oxford Nanopore Technologies and receive compensation and benefits from the company

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Patient consent was not required as these were routinely collected samples and stored as per normal protocols used for clinical practice. They did not contain any cellular material and were therefore not subject to HTA. Therefore, as for assay development, using anonymised samples, no IRAS/ethics was required or sought. Sheffield Teaching Hospital NHS Foundation Trust

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • This preprint applies only to research use of any products mentioned and not to a future version of product(s) to be marketed for IVD professional use.

Data Availability

The nucleotide sequences of the SARS-CoV-2 genomes used in the primer inclusivity and cross-reactivity analysis are available, upon free registration, from the GISAID database.

https://www.gisaid.org/

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted August 11, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing
Phillip James, David Stoddart, Eoghan D Harrington, John Beaulaurier, Lynn Ly, Stuart W Reid, Daniel J Turner, Sissel Juul
medRxiv 2020.08.07.20161737; doi: https://doi.org/10.1101/2020.08.07.20161737
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing
Phillip James, David Stoddart, Eoghan D Harrington, John Beaulaurier, Lynn Ly, Stuart W Reid, Daniel J Turner, Sissel Juul
medRxiv 2020.08.07.20161737; doi: https://doi.org/10.1101/2020.08.07.20161737

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (432)
  • Anesthesia (99)
  • Cardiovascular Medicine (946)
  • Dentistry and Oral Medicine (178)
  • Dermatology (109)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (420)
  • Epidemiology (8977)
  • Forensic Medicine (4)
  • Gastroenterology (419)
  • Genetic and Genomic Medicine (1943)
  • Geriatric Medicine (190)
  • Health Economics (401)
  • Health Informatics (1324)
  • Health Policy (657)
  • Health Systems and Quality Improvement (518)
  • Hematology (212)
  • HIV/AIDS (417)
  • Infectious Diseases (except HIV/AIDS) (10787)
  • Intensive Care and Critical Care Medicine (574)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (222)
  • Neurology (1822)
  • Nursing (109)
  • Nutrition (271)
  • Obstetrics and Gynecology (352)
  • Occupational and Environmental Health (470)
  • Oncology (996)
  • Ophthalmology (297)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (578)
  • Pharmacology and Therapeutics (275)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1894)
  • Public and Global Health (4117)
  • Radiology and Imaging (675)
  • Rehabilitation Medicine and Physical Therapy (365)
  • Respiratory Medicine (548)
  • Rheumatology (224)
  • Sexual and Reproductive Health (190)
  • Sports Medicine (177)
  • Surgery (207)
  • Toxicology (39)
  • Transplantation (109)
  • Urology (80)